Precision medicine oncology company IDEAYA Biosciences Inc (Nasdaq: IDYA) announced on Wednesday that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor for MTAP-deleted solid tumours.

The company plans to begin a Phase 1 dose escalation trial in MTAP-deleted lung cancer in the fourth quarter of 2025, with combination studies alongside IDE397, IDEAYA's proprietary MAT2A inhibitor, expected in the first half of 2026.

MTAP deletions occur in approximately 15-20% of non-small cell lung cancer. Preclinical studies suggest elevated MTA/SAM ratios in these tumours create a vulnerability to PRMT5 inhibition, which is enhanced with MAT2A blockade, highlighting a potential combination therapy opportunity in an area of substantial unmet need. IDEAYA also plans to explore IDE892 as monotherapy and in combination with IDE397 in additional high-priority MTAP solid tumour indications.

Preclinical data for IDE892 and the mechanistic rationale for combination therapy with IDE397 will be presented at IDEAYA's 10-Year Anniversary R&D Day on 8 September 2025.

IDEAYA Biosciences focuses on developing precision oncology therapies, leveraging small-molecule discovery, structural biology and biomarker-driven strategies to advance targeted, potentially first-in-class treatments for genetically defined cancers.